Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   HEPATITIS MONTHLY   JANUARY 2011 , Volume 11 , Number 1 (30); Page(s) 3 To 6.
 
Paper: 

HALOTHANE-INDUCED HEPATITIS: A FORGOTTEN ISSUE IN DEVELOPING COUNTRIES

 
 
Author(s):  HABIB ELAHI P., MAHBOUBI NASTARAN, ESMAEILI SARA, SAFARI SAEID, DABAGH ALI, ALAVIAN S.M.*
 
* BAQIYATALLAH RESEARCH CENTER FOR GASTROENTEROLOGY AND LIVER DISEASES, BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES AND TEHRAN HEPATITIS CENTER, TEHRAN, IR IRAN
 
Abstract: 

Halothane was introduced as an anesthetic in the 1950s and was considered a revolutionary agent in the field of anesthesia. Soon after, halothane-induced hepatitis became a concern, leading to the development of less toxic gases that induced a lower incidence of side effects. Two types of halothane-related hepatotoxicity have been described: type 1, or mild hepatitis, is associated with elevated transaminase levels and self-limiting symptoms, and type 2, or severe hepatotoxicity, is associated with acute fatal liver failure and is fatal in most cases. Hepatotoxicity is most likely to be immune related, based on much evidence. Free radicals that are produced by the metabolism of halothane in the liver can modify cellular proteins and introduce neo-antigens to the immune system. Sensitization to these neo-antigens induces a more severe response after multiple exposures; most cases of type 2 hepatitis occur after repeated contact. New halogenated anesthetics such as enflurane, sevoflurane, and desflurane, are not metabolized in the liver, causing few cases of sensitization. Compared with halothane, these anesthetics are expensive. As a result, replacement of halothane with new halogenated anesthetics requires a precise cost-benefit analysis, especially in developing countries that have low health care budgets.

 
Keyword(s): HALOTHANE, HEPATITIS, HALOGENATED, ANESTHETICS
 
 
References: 
  • ندارد
  •  
 
Click to Cite.
APA: Copy

HABIB ELAHI, P., & MAHBOUBI, N., & ESMAEILI, S., & SAFARI, S., & DABAGH, A., & ALAVIAN, S. (2011). HALOTHANE-INDUCED HEPATITIS: A FORGOTTEN ISSUE IN DEVELOPING COUNTRIES. HEPATITIS MONTHLY, 11(1 (30)), 3-6. https://www.sid.ir/en/journal/ViewPaper.aspx?id=188994



Vancouver: Copy

HABIB ELAHI P., MAHBOUBI NASTARAN, ESMAEILI SARA, SAFARI SAEID, DABAGH ALI, ALAVIAN S.M.. HALOTHANE-INDUCED HEPATITIS: A FORGOTTEN ISSUE IN DEVELOPING COUNTRIES. HEPATITIS MONTHLY. 2011 [cited 2021May07];11(1 (30)):3-6. Available from: https://www.sid.ir/en/journal/ViewPaper.aspx?id=188994



IEEE: Copy

HABIB ELAHI, P., MAHBOUBI, N., ESMAEILI, S., SAFARI, S., DABAGH, A., ALAVIAN, S., 2011. HALOTHANE-INDUCED HEPATITIS: A FORGOTTEN ISSUE IN DEVELOPING COUNTRIES. HEPATITIS MONTHLY, [online] 11(1 (30)), pp.3-6. Available: https://www.sid.ir/en/journal/ViewPaper.aspx?id=188994.



 
  pdf-File
Yearly Visit 69
 
Latest on Blog
Enter SID Blog